The research arm of investment banking firm Goldman Sachs
will look to promote Epocrates' marketing research services. Financial terms of
the three-year agreement were not disclosed.
Hudson Street, a Goldman Sachs business, will seek to
connect Epocrates to buyside investors and portfolio managers for use in
investigating potential pharma and biotech investments.
“We have a highly targeted panel that they can reach,” said
Kirk Loevner, Epocrates chairman and chief executive officer.
Epocrates claims 500,000 active clinician users in its
subscriber base. Of those, 200,000 are active US physicians, and 145,000 of
those have opted into the marketing research service.
Epocrates, also known for
its clinical information and decision support tools, already works with about
150 marketing research firms. They are drawn to the vendor's ability to tap into
its physician panel, by specialty and by geography, and get answers to surveys.